News

Public · Published

UBS maintains Alnylam Pharmaceuticals at Buy, lowers price target to $329 from $354

UBS kept its Buy rating on Alnylam Pharmaceuticals but cut its price target to $329 from $354, a 7.1% reduction. UBS said the new target represented 99.4% upside from the stock's October 30 closing price of $165.

Published:

Updated:

What happened

UBS kept its Buy rating on Alnylam Pharmaceuticals but cut its price target to $329 from $354, a 7.1% reduction. UBS said the new target represented 99.4% upside from the stock’s October 30 closing price of $165.

Confirmed

Global impact / market context

The lower target signals that UBS reduced its estimate of where Alnylam shares could trade, even while retaining a Buy rating. That change may influence investor expectations and positioning, but the article gives no reason for the cut or evidence of a company-level change.

Analyst inference

Recent analyst views were spread across a wide range: the five reported targets span $199 to $354, with ratings including Buy, Equal-Weight and Market Perform. This disagreement suggests investors face differing expectations; it does not establish which forecast will prove accurate.

Confirmed

What to watch

  1. Watch for any later UBS update explaining the lower target or changing its Buy rating; the article provides no rationale for the revision. Analyst inference
  2. Compare future analyst targets and ratings with the reported $199–$354 range to see whether the spread narrows or widens. Analyst inference
  3. Track whether Alnylam’s subsequent company disclosures provide information that could clarify the differing analyst expectations; no such developments are reported here. Analyst inference

Evidence

  • Original source link unavailable